US 7,776,822 B2Granted

Intrathecal and intratumoral superantigens to treat malignant disease

AssigneeJenquest

InventorDavid S. Terman

Life of this patent

Estimating the term…

Loading patent…

Abstract

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

Claims4

Dependent claims

A method of treating a subject with a carcinoma comprising administering to said subject parenterally by infusion or injection a tumoricidally effective amount of a composition consisting of:

(i) a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin protein which native protein:
(a) has the biological activity of stimulating T cell mitogensis via a T cell receptor vβ region or
(ii) a biologically active homologue or fragment of a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin, which homologue or fragment:
(a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor vβ region and
(b) has sequence homology characterized as a z value exceeding 13 when the sequence of the homologue or said fragment is compared to the sequence of a native staphylococcal enterotoxin or a native streptococcal progenic exotoxin, determined by FASTA analysis using gap penalties of -12 and -2, Blosum 50 matrix and Swiss-PROT or PIR database;
or
(iii) a biologically active fusion protein having said biological activity and said sequence homology, comprising
(A) said homologue,
(B) a native staphylococcal enterotoxin,
(C) a native streptococcal pyrogenic exotoxin, or
(D) a biologically active fragment of said homologue, said native enterotoxin or said native exotoxin,
fused to a peptide or polypeptide fusion partner, wherein a chemotherapeutic drug or drugs is/are administered parenterally by infusion or injection before, together with or after administration of said enterotoxin or exotoxin composition.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/513,466Filed 8 May 2003
Published: US 2006/0052295 A19 Mar 2006
Granted: 17 Aug 2010
Term ends: Not estimatedThe source records don’t support an estimate.

Classification28 codes

A61K 38/164
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from bacteria
A61K 39/085
Bacterial antigens: staphylococcus
A61K 40/10
Cellular immunotherapy: characterised by the cell type used
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…